Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma (NCT04598009)
A Phase II Study of Binimetinib in Combination With Imatinib in Patients With Advanced KIT-Mutant Melanoma
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be removed by surgery (unresectable). Binimetinib and imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and imatinib may help treat patients with KIT-mutant melanoma.
Who can join: Review the eligibility criteria below.
Location: UC San Diego Moores Cancer Center — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- UC San Diego Moores Cancer Center — La Jolla, California
- University of California, San Francisco — San Francisco, California
📞 Contact the Study Coordinator
Phone: (415) 514-6427
Email: sonia.contrerasmartinez@ucsf.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Melanoma Stage III
- Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab — Durham, North Carolina
- Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis — Boston, Massachusetts
- SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab — Miami, Florida
- Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma — Washington D.C., District of Columbia
- Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma — Tampa, Florida
Explore by condition: All Melanoma Stage III clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.